At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Not Yet Opened 09-17 16:00:00 EDT
2.71
-3.97
-59.43%
盘后2.73
+0.02+0.74%
19:59 EDT
High3.35Low2.70Vol1.44M
Open3.23D1 Closing6.68Amplitude9.73%
Mkt Cap8.56MTradable Cap7.39MTotal Shares3.16M
T/O4.25MT/O Rate52.91%Tradable Shares2.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Top Midday Decliners
MT Newswires Live  ·  02:36
Top Midday Decliners
Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial
TIPRANKS  ·  00:44
Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial
Stocks to Watch: Generac, Vicor, Longeveron, Viant
Dow Jones  ·  09-17 06:34
Stocks to Watch: Generac, Vicor, Longeveron, Viant
Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition
Reuters  ·  09-17 06:15
Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition
Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint
Dow Jones  ·  09-17 05:55
Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint
Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint
Reuters  ·  09-17 05:45
Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint
Longeveron to resume trading at 5:55 pm ET
TIPRANKS  ·  09-17 05:40
Longeveron to resume trading at 5:55 pm ET
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial
TIPRANKS  ·  09-17 05:35
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial
Longeveron exploring all options for maximizing shareholder value
TIPRANKS  ·  09-17 05:35
Longeveron exploring all options for maximizing shareholder value
Longeveron Announces Topline Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
THOMSON REUTERS  ·  09-17 05:27
Longeveron Announces Topline Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
Longeveron - no Deaths in Laromestrocel-Treated Patients over 12 Months
THOMSON REUTERS  ·  09-17 05:27
Longeveron - no Deaths in Laromestrocel-Treated Patients over 12 Months
Longeveron - Company Initiates Process to Optimize Cost Containment and Maximize Shareholder Value
THOMSON REUTERS  ·  09-17 05:27
Longeveron - Company Initiates Process to Optimize Cost Containment and Maximize Shareholder Value
Longeveron: Intends to Pursue Funding Sources & Other Potential Revenue Opportunities to Advance Laromestrocel in Longevity & Aging-Related Frailty
THOMSON REUTERS  ·  09-17 05:27
Longeveron: Intends to Pursue Funding Sources & Other Potential Revenue Opportunities to Advance Laromestrocel in Longevity & Aging-Related Frailty
Longeveron Inc: Initiated a Process to Review All Options
THOMSON REUTERS  ·  09-17 05:27
Longeveron Inc: Initiated a Process to Review All Options
Longeveron - Elpis Ii Trial Did not Meet Primary Endpoint of Rvef Improvement at Month 12
THOMSON REUTERS  ·  09-17 05:27
Longeveron - Elpis Ii Trial Did not Meet Primary Endpoint of Rvef Improvement at Month 12
Longeveron Inc trading halted, news pending
TIPRANKS  ·  09-17 04:55
Longeveron Inc trading halted, news pending
NASDAQ Trade Halt Halt News Pending at 04:55 Pm
Reuters  ·  09-17 04:55
NASDAQ Trade Halt Halt News Pending at 04:55 Pm
Longeveron Regains Nasdaq Compliance With Minimum Bid Price
TIPRANKS  ·  09-15
Longeveron Regains Nasdaq Compliance With Minimum Bid Price
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire  ·  09-03
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron CFO Nirav S. Jhaveri Files Initial Beneficial Ownership Statement
Reuters  ·  08-26
Longeveron CFO Nirav S. Jhaveri Files Initial Beneficial Ownership Statement

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--